Cardiovascular Safety of Biologics Targeting IL-12 or IL-23 Cardiovascular Safety of Biologics Targeting IL-12 or IL-23

Do the biologics briakinumab and ustekinumab, which target interleukin-12 and IL-23 in the treatment of psoriasis, increase the risk of cardiovascular disease?American Journal of Clinical Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news